# A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

Source: https://onco.cc/trials/nct06499350/  
OnCo record `nct06499350` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Tislelizumab in advanced solid tumours, run by FindCure Biosciences (ZhongShan) Co., Ltd., now recruiting.

## Summary

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT06499350 by FindCure Biosciences (ZhongShan) Co., Ltd., with 33 participants planned, started 2024-11-13 and due to reach its primary completion in 2026-12-01. Interventions recorded: FC084CSA+Tislelizumab combination (dose escalation) and RP2D of FC084CSA+Tislelizumab combination (dose expansion).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06499350
- Phase: 1/2
- Setting: A Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of AXL Inhibitor FC084CSA Tablets in Combination With Tislelizumab in the Treatment of Advanced Malignant Solid Tumors
- Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd.
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT06499350: https://clinicaltrials.gov/study/NCT06499350

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06499350.json